Moderna Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK) announced five-year follow-up data from their Phase 2b melanoma study showing sustained ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE